(NASDAQ: SEPN) Septerna's forecast annual revenue growth rate of 734.76% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 290.64%, and it is also forecast to beat the US market's average forecast revenue growth rate of 58.92%.
Septerna's revenue in 2025 is $726,000.On average, 7 Wall Street analysts forecast SEPN's revenue for 2025 to be $3,399,839,469, with the lowest SEPN revenue forecast at $477,997,232, and the highest SEPN revenue forecast at $6,569,619,642. On average, 7 Wall Street analysts forecast SEPN's revenue for 2026 to be $1,864,550,346, with the lowest SEPN revenue forecast at $0, and the highest SEPN revenue forecast at $4,447,367,216.
In 2027, SEPN is forecast to generate $1,534,843,272 in revenue, with the lowest revenue forecast at $218,467,162 and the highest revenue forecast at $2,340,719,588.